[ GlycoAdvance, NTEC ]
Friday June 29, 2:38 pm Eastern Time
Press Release
Two Biopharmaceutical Companies Present Positive Results
With Neose's GlycoAdvance Technology at BIO 2001 Meeting
HORSHAM, PA--(BW HEALTHWIRE)--June 29, 2001--Neose Technologies, Inc. (Nasdaq NM:
NTEC - news) today announced that two companies with which Neose has been collaborating presented
publicly certain results of their previously undisclosed feasibility studies using GlycoAdvance(TM)
technology. The presentations were made as part of a BIO 2001 meeting symposium entitled,
``Glycosylation in the Era of Proteomics: Will Sugars be the Limiting Factor in Protein Production?''
At the symposium, scientists from Biogen, Inc. and Eli Lilly and Company presented results of experiments
in which glycoproteins produced conventionally in Chinese hamster ovary (CHO) cell lines were further
glycosylated by Neose's proprietary GlycoAdvance methods. Before and after being exposed to
GlycoAdvance enzyme-based glycosylation, the glycoproteins were analyzed for sialic acid content, and
tested for circulatory half-life in vivo. The half-life data were generated in mice, in one case, and in
primates in the second case.
The Biogen and Eli Lilly scientists announced that in general, GlycoAdvance technology resulted in nearly
complete restoration of the target sugars to the glycoproteins. More significantly, increased glycosylation
allowed increased stability in vivo. Steady-state half-lives increased by greater than two-fold, and bolus
half-lives increased as much as three-fold.
Neose develops proprietary technologies for the synthesis and manufacture of complex carbohydrates.
The Company uses its broad technology platform in the following programs: GlycoAdvance uses our
innovative technologies to address the problems of incomplete or incorrect glycosylation encountered in
the manufacture of recombinant glycoproteins; GlycoTherapeutics uses our technology platform to
develop and produce novel carbohydrate-based therapeutics; and GlycoActives uses our technology
platform to develop and produce novel carbohydrate-based food ingredients.
For more information, please visit www.neose.com.
``Safe Harbor'' Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are
not historical facts are ``forward-looking statements'' that involve risks and uncertainties. Specifically, the results presented by
the Company's collaborators are limited and preliminary, and are not necessarily indicative of actual results that may be
obtained in humans, or in connection with other protein drug candidates. Although the Company has conducted limited
evaluative feasibility studies with the collaborators named in this press release, the Company has not entered into any long-term
license or other collaborative agreements with either company. For a more detailed discussion of these risks and uncertainties,
any of which could cause the Company's actual results to differ from those contained in any forward-looking statement, see the
``Risk Factors'' section of Item 1 of the Company's Annual Report on Form 10-K for the year ended December 31, 2000.
Contact:
Neose Technologies, Inc.
P. Sherrill Neff, A. Brian Davis
215/441-5890
E-mail: info@neose.com
or
Adam Friedman Associates LLC
Adam Friedman, 212/981-2529
E-mail: ntec@adam-friedman.com
or
The Redstone Group, LLC
Jason Rubin, 610/941-2741 |
